Latest news with #AutolusTherapeuticsplc
Yahoo
3 days ago
- Automotive
- Yahoo
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12, keeping the price target at $10.00. The analyst cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating, stating that the updated analysis highlights a notable number of patients in remission with no need for further therapy. This is a positive indicator, according to the analyst, especially in comparison to other treatments such as Tecartus. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. While the analyst acknowledged that 38% of responders were still in remission with a median follow-up of 33 months, a slight drop from the 40% reported at 21.5 months, he stated that the results are still impressive. He also cited other promising factors, including the overall survival and event-free survival rates, as well as the absence of new safety concerns. According to Blum, these factors suggest a positive reception from physicians and the potential for higher commercial adoption of obe-cel, supporting the optimistic outlook for Autolus Therapeutics plc (NASDAQ:AUTL). Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, with a focus on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
29-05-2025
- Business
- Yahoo
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences. William Blair 45th Annual Growth Stock ConferenceManagement to host investor meetingsDate: June 3, 2025Location: Chicago, IL Jefferies Global Healthcare ConferenceFireside Chat PresentationDate and time: June 5, 2025; 3:10pm EDT / 20:10pm BSTLocation: New York, NYPresenter: Chief Executive Officer Dr. Christian Itin Goldman Sachs 46th Annual Global Healthcare ConferenceFireside Chat PresentationDate and time: June 11, 2025; 1:20pm EDT / 18:20 BSTLocation: Miami, FLPresenter: Chief Financial Officer Rob Dolski A webcast of the fireside chats will be available on the 'Events' page in the 'Investor Relations & Media' section of the Company's website at A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Autolus Therapeutics plcAutolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit Contact: Amanda Cray +1 617-967-0207 Olivia Manser +44 7780 471 568 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Automotive
- Yahoo
Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential
We recently published an article titled . Autolus Therapeutics plc (NASDAQ:AUTL) was one of the stocks that was covered in that article. Wall Street analysts believe AUTL has a 697% upside potential over the next 12 months. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company specializing in the development of T-cell therapies for the treatment of cancer and autoimmune diseases. Established in 2014, Autolus is advancing innovative approaches in the field of chimeric antigen receptor (CAR) T-cell therapy, aiming to transform patient outcomes with cutting-edge science and technology. Autolus has strategically positioned itself to meet global demand through its dedicated commercial manufacturing facility, known as "The Nucleus," located in the UK. This facility not only supports clinical and commercial production requirements but also ensures scalability and flexibility, enabling the company to cater to expanding markets. Autolus retains worldwide commercial rights to its products and maintains a focused marketing strategy targeting key regions such as the United States, the United Kingdom, and Europe. This strategic approach highlights the company's commitment to delivering transformative therapies across diverse geographic markets while ensuring the highest standards of quality in production. Further analysis of the company's business model and financial performance reflect its significant progress in advancing CAR T-cell therapy. In the first quarter of 2025, Autolus posted revenue of $9 million, demonstrating steady growth. For the full year of 2024, the company reported $45.8 million in revenue, driven by its pioneering efforts in cancer treatment development. With $210 million in cash reserves, Autolus is well-positioned to support the commercialization plans for its therapies and sustain future research and development endeavors. This financial stability has contributed to a positive outlook among analysts, who project the company's share price to reach $9.97 within the next twelve months, offering an upside potential of 697.60%. Through its relentless pursuit of innovation and financial health, Autolus Therapeutics plc remains at the forefront of oncology treatment, pushing boundaries and redefining possibilities in CAR T-cell therapy. Overall, Autolus Therapeutics plc (NASDAQ:AUTL) ranks 3rd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey.
